Australia's productivity slump threatens economic growth
Australia's economic engine is stalling as labour productivity slipped by 0.6% in the March quarter.
Australia's economic engine is stalling as labour productivity slipped by 0.6% in the March quarter.
Genmab (NASDAQ:GMAB) announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, which evaluates the subcutaneous T-cell engaging bispecific antibody epcoritamab in combination with rituximab and lenalidomide (epcoritamab plus R2).
Canaan (NASDAQ:CAN) announced its unaudited operational updates for May 2026, highlighting significant advancements in energy efficiency and geographic infrastructure expansions.
C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.
Purple Biotech (NASDAQ:PPBT) unveiled new preclinical data for IM1240, its lead T-cell engager candidate utilizing the proprietary CAPTN-3 platform, at the European Association for Cancer Research (EACR) 2026 Congress.
Climb Bio (NASDAQ:CLYM) reported positive initial Phase 1b clinical data for its drug candidate budoprutug, an anti-CD19 monoclonal antibody, which is being developed to treat adults with primary immune thrombocytopenia.
Vera Bradley (NASDAQ:VRA) reported an unexpected rise in profit margins and its first quarterly top-line expansion in over four years, signaling that its comprehensive brand overhaul is beginning to resonate with retail consumers.
Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.
Silence Therapeutics (NASDAQ:SLN) reported positive follow-up and quality-of-life clinical data for its experimental blood cancer treatment, divesiran, demonstrating a sustained reduction in the medical procedures required to manage the rare disease.
Driven Brands Holdings (NASDAQ:DRVN) reported a rise in profit and revenue for the first quarter of fiscal 2026, supported by robust performance in its quick-lube business even as the company navigates elevated corporate expenses stemming from its recent financial restatements.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy